Almost Half Off DILI/Hepatotoxicity Studies Until the End of July
Drug induced liver injury (DILI) or hepatotoxicity is one of the leading causes of adverse events during clinical trials, which often results in failures or clinical holds during the development of new drug candidates. Our SEKISUI partner lab, the Drug Development Solutions Center, offers in vitro studies to evaluate a drug candidate for DILI potential, including cholestatic DILI and mitochondrial toxicity assessments. These assays are designed to allow you to develop a comprehensive ‘risk matrix’ to assess risk of liver injury by exploring well-characterized mechanisms that could impair hepatic function.
For a limited time, we are offering these critical studies at a 46% discount. Studies must be booked by July 30th and test articles must be received by August 6th to receive the discount. The discount applies to the standard study list price for your area and cannot be combined with other offers or discounts.